✦ LIBER ✦

95 EFFICACY AND SAFETY OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN IN PREVIOUSLY NULL-RESPONDER GENOTYPE 1 HCV PATIENTS

✍ Scribed by D.R. Nelson; R.H. Ghalib; M. Sulkowski; E. Schiff; V. Rustgi; P.J. Pockros; C. Wang; G. Decosterd Kerhuel; P. Grosgurin; H. Porchet; R. Crabbe

Book ID: 117377106
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 51 KB
Volume: 50
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(09)60097-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

143 EFFICACY AND SAFETY OF INCREASING DO

143 EFFICACY AND SAFETY OF INCREASING DOSES OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A IN TREATMENT NAIVE CHRONIC HCV PATIENTS

✍ R. Flisiak; S.V. Feinman; M. Jablkowski; A. Horban; W. Kryczka; W. Halota; J.E. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB

1210 ABT-267 COMBINED WITH PEGYLATED INT

1210 ABT-267 COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12 WEEK ANTIVIRAL AND SAFETY ANALYSIS

✍ Sullivan, G.J.; Rodriques-Torres, M.; Lawitz, E.; Poordad, F.; Kapoor, M.; Campb 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 117 KB

1045 SAFETY AND ANTIVIRAL EFFICACY OF 14

1045 SAFETY AND ANTIVIRAL EFFICACY OF 14 DAYS OF THE CYCOPHILIN INHIBITOR NIM811 IN COMBINATION WITH PEGYLATED INTERFERON α2a IN RELAPSED GENOTYPE 1 HCV INFECTED PATIENTS

✍ Lawitz, E.; Rouzier, R.; Nguyen, T.; Huang, M.; Ke, J.; Praestgaard, J.; Serra, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 91 KB

2009 SAFETY AND ANTIVIRAL ACTIVITY OF AN

2009 SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS

✍ Lawitz, E.; Rodriquez-Torres, M.; Rustgi, V.K.; Hassanein, T.; Rahimy, M.H.; Cro 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 51 KB

751 The safety and efficacy of viramidin

751 The safety and efficacy of viramidine® plus pegylated interferon alpha-2B versus ribavirin plus pegylated interferon alpha-2B in therapy-naïve patients infected with HCV: Phase 3 results

✍ Y. Benhamou; P. Pockros; M. Rodrieuez-Torres; S. Gordon; M. Shiffinan; Y. Lurie; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 117 KB

Safety and efficacy of faldaprevir with

Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection

✍ Nishiguchi, Shuhei; Sakai, Yoshiyuki; Kuboki, Makoto; Tsunematsu, Satoshi; Urano 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 276 KB